Basson R P, Ghosh A, Cerimele B J, DeSante K A, Howey D C
Lilly Laboratory for Clinical Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Pharm Res. 1998 Feb;15(2):276-9. doi: 10.1023/a:1011974803996.
Peak drug concentration (Cmax) measures the extremity of drug exposure and is a secondary indicator of the extent of absorption after area under the concentration time curve (AUC). Cmax serves as the indicator of absorption rate in bioequivalence (BE) studies in the US (1). The use of Cmax, not the time to Cmax (Tmax), as the metric to assess absorption rate causes erratic inferences in BE studies, and incorrect conclusions for some. We can improve BE efficiency (i.e., get the answer right the first time), by properly analyzing the time to Cmax (Tmax) instead of Cmax.
We have previously redirected attention to Tmax as the unconfounded absorption rate variable, instead of Cmax, and have called for equally spaced sampling times during the suspected absorption phase to improve the performance of the rate metric (2). Equal spacing converts Tmax easily into a count variable and we illustrated an appropriate statistical analysis for counts. This paper provides some measurement theory concepts to help judge which is the more appropriate analysis, and also provides parametric confidence limits for Tmax treatment differences. Three separate BE studies are then analyzed by both methods.
By focusing on the differences in conclusions, or inferences, this paper identifies three major issues with the current FDA "recommended" analysis of BE studies. First, Cmax, a continuous variable peak-height or extent measure has usurped Tmax's function and performs erratically as a substitute measure for the rate of absorption. Second, Tmax, should be analyzed as a discrete attribute, not as a continuous variable. Third, since several extent measures (AUC, Cmax), not one, are actually being analyzed, an adjustment for multiple testing is mandatory if we are to maintain the size of the test at the desired alpha level (13), and not inadvertently use a narrower bioequivalence window than is intended. These actions all can have serious unintended consequences on inferences, including making inappropriate ones.
药物峰浓度(Cmax)衡量药物暴露的极值,是浓度-时间曲线下面积(AUC)后吸收程度的次要指标。在美国的生物等效性(BE)研究中,Cmax用作吸收速率的指标(1)。使用Cmax而非达峰时间(Tmax)作为评估吸收速率的指标,会在BE研究中导致不稳定的推断,对一些研究得出错误结论。通过正确分析达峰时间(Tmax)而非Cmax,我们可以提高BE效率(即首次就得出正确答案)。
我们之前已将注意力重新转向Tmax,将其作为无混淆的吸收速率变量,而非Cmax,并呼吁在疑似吸收阶段采用等间距采样时间,以提高速率指标的性能(2)。等间距可轻松将Tmax转换为计数变量,我们还阐述了针对计数的适当统计分析方法。本文提供了一些测量理论概念,以帮助判断哪种分析更合适,还提供了Tmax处理差异的参数置信限。然后用这两种方法对三项独立的BE研究进行分析。
通过关注结论或推断中的差异,本文确定了当前美国食品药品监督管理局(FDA)“推荐”的BE研究分析存在的三个主要问题。首先,Cmax作为一个连续变量的峰高或程度指标,篡夺了Tmax的功能,作为吸收速率的替代指标表现不稳定。其次,Tmax应作为离散属性进行分析,而非连续变量。第三,由于实际上分析的是多个程度指标(AUC、Cmax),而非一个,如果要将检验规模维持在期望的α水平(13),则必须进行多重检验调整,且不能无意中使用比预期更窄的生物等效性窗口。这些行为都可能对推断产生严重的意外后果,包括得出不恰当的推断。